Positive outcome of the pivotal Phase III study with PQ Grass 27600 SU, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine (MCT) and Monophosphoryl Lipid A (MPL) as adjuvant system

Authors
Category Primary study
ConferenceAllergologie
Year 2024
This article has no abstract
Epistemonikos ID: 7a45960280a332d6838b0b0160325da1a4da61fc
First added on: Apr 30, 2026